Lupin receives USFDA nod for testosterone topical solution

Lupin logo

 

Lupin announced that it has received the final approval from for its testosterone topical solution from USFDA to market a generic version of Eli Lilly and Company’s Axiron Topical solution.

According to IMS MAT June 2017 data, testosterone topical solution had sales of $244.2 million in the US.

The testosterone topical solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.